Kutti J, Bergström A L
Scand J Rheumatol. 1981;10(4):266-8. doi: 10.3109/03009748109095312.
Duplicate platelet survival studies were carried out on 10 patients with SLE. At the time of the first study 5 of them (group I) were untreated and the remaining 5 (group II) were receiving corticosteroid (CS) therapy. The second study was performed while group I patients received CS and group II patients CS + azathioprine (AT) treatment. Untreated SLE patients were shown to have normal values for platelet mean life-span (MLS) and platelet production rate. CS and AT treatment did not affect either platelet MLS or platelet production rate. The present study also provides further evidence that a state of compensated thrombocytolysis is not present in SLE.
对10例系统性红斑狼疮(SLE)患者进行了重复的血小板存活研究。在首次研究时,其中5例(第一组)未接受治疗,其余5例(第二组)正在接受皮质类固醇(CS)治疗。第二次研究是在第一组患者接受CS治疗而第二组患者接受CS+硫唑嘌呤(AT)治疗时进行的。未治疗的SLE患者血小板平均寿命(MLS)和血小板生成率值正常。CS和AT治疗对血小板MLS或血小板生成率均无影响。本研究还进一步证明SLE不存在代偿性血小板溶解状态。